Moderna COVID-19 Vaccine, Bivalent is now authorized
The updated booster from Moderna is designed to help protect against multiple COVID-19 variants in a single shot.
What is a Bivalent Vaccine?
Bivalent vaccines are designed to protect against 2 strains of a virus providing greater protection against variants.
Why should patients get a Bivalent Vaccine?
A bivalent is recommended because it's the only type of vaccine that can protect against the most dominant Omicron strains of COVID-19 in the US.
With the rise of more contagious variants, people need greater protection, even with prior vaccination or immunity from COVID-19 infection.
Vaccine Overview for
Adult Primary Series Vaccination
Looking for information on adult primary series vaccination?Visit HCP site for spikevax
(COVID‑19 vaccine, mRNA)
2.5 mL vial for
primary series doses (age 6 months-5 years)
5.5 mL vial for
booster dose (age 18
and older) or primary series doses (age 12 and older)
2.5 mL vial for booster dose (age 18 and older) or primary series doses (age 6-11 years)
Dosing and Administration
The Moderna COVID‑19 Vaccine is administered as a primary series by intramuscular injection of two doses (0.5 mL each) 1 month apart to individuals 6 years of age or older or two doses (0.25 mL each) 1 month apart to individuals 6 months-5 years of age.
A third primary series dose of the Moderna COVID‑19 Vaccine (0.5 mL or 0.25 mL, depending on age) at least 1 month following the second dose is authorized for administration to individuals at least 6 months of age who have undergone solid organ transplantation, or who are diagnosed with conditions that are considered to have an equivalent level of immunocompromise.
Booster Dosing and Administration
The booster dose of Moderna COVID-19 Vaccine may be administered from two different vial presentations. When using the 5.5 mL multiple-dose vial with a red cap and a label with a blue border, the dose is 0.25 mL. When using the booster-only multiple-dose vial with a dark blue cap and a label with a purple border, the booster dose is 0.5 mL.
A first Moderna COVID‑19 Vaccine booster dose may be administered intramuscularly at least 5 months after completing a primary series of the Moderna COVID‑19 Vaccine or spikevax (COVID-19 Vaccine, mRNA) to individuals 18 years of age or older.
A first booster dose of the Moderna COVID‑19 Vaccine may be administered as a heterologous booster dose following completion of primary vaccination with another authorized or approved COVID‑19 vaccine. The dosing interval for the heterologous booster dose is the same as that authorized for a booster dose of the vaccine used for primary vaccination.
A second booster dose of the Moderna COVID‑19 Vaccine may be administered to individuals 50 years of age and older at least 4 months after receipt of a first booster dose of any authorized or approved COVID‑19 vaccine.
A second booster dose of the Moderna COVID‑19 Vaccine may be administered at least 4 months after receipt of a first booster dose of any authorized or approved COVID‑19 vaccine to individuals 18 years of age and older with certain kinds of immunocompromise.Get full dosing details
Clinical Trial Data
The Moderna COVID‑19 Vaccine is being evaluated in an ongoing Phase 3 randomized, placebo‑controlled, observer‑blind clinical trial conducted in the United States.See clinical trial data